Verrica Pharmaceuticals/VRCA

$5.55

2.78%
-
1D1W1MYTD1YMAX

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: VP-102, VP-315 and VP-103. The Company's lead product candidate, VP-102, is a drug-device combination that contains a GMP-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, a contagious and primarily pediatric viral skin disease; external genital warts (EGW), and common warts. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma and non-metastatic Merkel cell carcinoma. The Company is also developing its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot.

Ticker

VRCA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ted White

Employees

22

Headquarters

West chester, United States

VRCA Metrics

BasicAdvanced
$217.89M
Market cap
-
P/E ratio
-$1.07
EPS
1.87
Beta
-
Dividend rate

What the Analysts think about VRCA

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
131.17% upside
High $18.00
Low $8.00
$5.55
Current price
$12.83
Average price target

VRCA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-855.17% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.9M
2,800%
Net income
$-24.8M
127.52%
Profit margin
-855.17%
-92.15%

VRCA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.15
-$0.24
-$0.54
-
Expected
-$0.19
-$0.19
-$0.21
-$0.36
-$0.53
Surprise
-27.27%
-21.05%
14.18%
49.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Verrica Pharmaceuticals stock

Buy or sell Verrica Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing